A team at the University of Barcelona has shown that tirzepatide, the drug sold as Mounjaro and Zepbound, switches on brown fat in obese mice. Brown adipose tissue burns energy to make heat instead of storing it, and the activation appeared even when treated mice were compared with untreated mice fed the same amount of food. Marion Peyrou, who led the work, cautions that the result comes from mice and may not carry over to people.
The study matters because it points past appetite. Tirzepatide’s weight loss is generally attributed to eating less. The Barcelona experiment was built to ask whether anything else is going on in the fat itself, using a food-matched comparison that separates the drug’s direct effect from the effect of a smaller appetite, and the answer so far applies only to rodents.
The pair-fed mouse design
The researchers used male C57BL/6J mice made obese on a high-fat diet. According to the paper in Biomedicine & Pharmacotherapy, the animals received tirzepatide by injection at 10 nanomoles per kilogram for five days and 20 nanomoles per kilogram for seven more. Alongside the treated and untreated groups, a pair-fed group ate only as much as the treated mice, which strips appetite suppression out of the comparison. Co-authors listed on the paper include Francesc Villarroya, Marta Giralt and Anna Planavila alongside Peyrou, and the paper appeared in volume 195 of the journal in February 2026.
That control is the heart of the work. A drug that makes animals eat less will shrink fat depots and alter blood chemistry whatever else it does, so a fair test has to match food intake. As The Brighter Side of News summarised the design, weight loss was equal in the tirzepatide and pair-fed groups over the 12 days, which indicates that reduced eating accounts for most of the weight change.
Brown fat thermogenesis and batokines
Brown fat is a different tissue from the white fat that stores surplus calories. Its cells are packed with mitochondria that, when switched on, burn glucose and fatty acids to produce heat, which is why the tissue is called calorie-burning. It also releases signalling molecules, the batokines, that reach other organs. A drug that stimulated it would in principle lower blood sugar and blood fats by a route separate from eating less, and that is the possibility the Barcelona group set out to test.
Where the groups diverged was in the brown fat. The authors report that tirzepatide significantly activated brown adipose tissue thermogenesis, with a marked reduction in the size of lipid droplets inside the cells and higher activity in genes tied to heat production and mitochondrial function. In the pair-fed mice, brown fat thermogenesis went down, the opposite direction.
Peyrou described the finding in the University of Barcelona’s account, which ScienceDaily carried: the activation is associated with an increased capacity to burn metabolic energy and with the production of batokines, molecules released by brown fat that benefit metabolism. Tirzepatide acts on two hormone receptors at once, those for GIP and GLP-1, and the Barcelona work suggests part of its effect runs through this tissue.
Other fat depots responded differently. In subcutaneous fat the drug altered lipid metabolism, and in visceral fat it reduced lipid accumulation, effects the paper says occurred independently of the lower calorie intake. Blood glucose fell further than in pair-fed mice and triglycerides dropped significantly, whereas the food-matched group showed little change in triglycerides, according to the summary of the results.
Limits of a mouse result
Nothing here measures a person. Peyrou said that because the work was done in mice, there may be significant differences between species and caution is needed. Mice carry far more brown fat, relative to body size, than adult humans do, and they lose heat quickly, so a drug that stimulates brown fat could matter more in a mouse than in a patient. The doses were also set for rodents and given over only 12 days, a short course set against the months of dosing that people take.
The paper itself treats human brown fat as an open question. As the Brighter Side summary reports, the authors say it remains unknown whether human brown fat responds to tirzepatide, and they point to a clinical trial named TABFAT that is meant to test it with direct brown-fat measurement; results from that trial are not yet available. Coverage in SciTechDaily and Mirage News repeats the same caveat, and both describe the work as a mouse study.
The claim the data support is narrow: in obese mice on a high-fat diet, tirzepatide activated brown fat beyond what reduced eating alone produced. Whether that contributes to the metabolic improvements patients see on Mounjaro is the question the TABFAT human trial, not this study, will have to answer.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Doctors warn a silent liver disease now affects one in three American adults
- Hackers are hijacking outdated home routers, and the FBI named the models to check
- Older Teslas are wearing out in ways early owners never saw coming
- Early electric-car owners are hitting battery and screen failures no one warned them about
